Dr Weeks’ Comment: Dr Tom Seyfried has taught the world much about brain cancer treatments.

“…The calorie restricted ketogenic diet (KD-R) is an anti-angiogenic, anti-inflammatory and pro-apoptotic metabolic therapy that also reduces fermentable fuels in the tumor microenvironment. Metabolic therapy, as an alternative to the standard of care, has the potential to improve outcome for patients with GBM and other malignant brain cancers…”

Review in Cancer Lett. 2015 Jan 28;356(2 Pt A):289-300. doi: 10.1016/j.canlet.2014.07.015. Epub 2014 Jul 25.

Metabolic therapy: a new paradigm for managing malignant brain cancer

Thomas N Seyfried ¹, Roberto Flores ², Angela M Poff ³, Dominic P D’Agostino ³, Purna Mukherjee ²Affiliations expand

• PMID: 25069036
• DOI: 10.1016/j.canlet.2014.07.015

Abstract

Little progress has been made in the long-term management of glioblastoma multiforme (GBM), considered among the most lethal of brain cancers. Cytotoxic chemotherapy, steroids, and high-dose radiation are generally used as the standard of care for GBM. These procedures can create a tumor microenvironment rich in glucose and glutamine. Glucose and glutamine are suggested to facilitate tumor progression. Recent evidence suggests that many GBMs are infected with cytomegalovirus, which could further enhance glucose and glutamine metabolism in the tumor cells. Emerging evidence also suggests that neoplastic macrophages/microglia, arising through possible fusion hybridization, can comprise an invasive cell subpopulation within GBM. Glucose and glutamine are major fuels for myeloid cells, as well as for the more rapidly proliferating cancer stem cells. Therapies that increase inflammation and energy metabolites in the GBM microenvironment can enhance tumor progression. In contrast to current GBM therapies, metabolic therapy is designed to target the metabolic malady common to all tumor cells (aerobic fermentation), while enhancing the health and vitality of normal brain cells and the entire body. The calorie restricted ketogenic diet (KD-R) is an anti-angiogenic, anti-inflammatory and pro-apoptotic metabolic therapy that also reduces fermentable fuels in the tumor microenvironment. Metabolic therapy, as an alternative to the standard of care, has the potential to improve outcome for patients with GBM and other malignant brain cancers.

Cited by 67 articles

• Metabolically Supported Chemotherapy for Managing End-Stage Breast Cancer: A Complete and Durable Response.İyikesici MS, Slocum AK, Winters N, Kalamian M, Seyfried TN.Cureus. 2021 Apr 26;13(4):e14686. doi: 10.7759/cureus.14686.PMID: 33927959 Free PMC article.
• The Glioblastoma Microenvironment: Morphology, Metabolism, and Molecular Signature of Glial Dynamics to Discover Metabolic Rewiring Sequence.Virtuoso A, Giovannoni R, De Luca C, Gargano F, Cerasuolo M, Maggio N, Lavitrano M, Papa M.Int J Mol Sci. 2021 Mar 24;22(7):3301. doi: 10.3390/ijms22073301.PMID: 33804873 Free PMC article. Review.
• Metabolomics of Glioma.Feng S, Liu Y.Adv Exp Med Biol. 2021;1280:261-276. doi: 10.1007/978-3-030-51652-9_18.PMID: 33791988
• Metabolic-targeted Combination Therapy With Dichloroacetate and Metformin Suppresses Glioblastoma Cell Line Growth In Vitro and In Vivo.Korsakova L, Krasko JA, Stankevicius E.In Vivo. 2021 Jan-Feb;35(1):341-348. doi: 10.21873/invivo.12265.PMID: 33402483 Free PMC article.